Eurosurv. Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in

[tetano]

• Yaniv Lustig[SUP]1,2,*[/SUP] , Neta Zuckerman[SUP]1,*[/SUP] , Ital Nemet[SUP]1[/SUP] , Nofar Atari[SUP]1[/SUP] , Limor Kliker[SUP]1[/SUP] , Gili Regev-Yochay[SUP]2,3[/SUP] , Einav Sapir[SUP]2,3[/SUP] , Orna Mor[SUP]1,2[/SUP] , Sharon Alroy-Preis[SUP]4[/SUP] , Ella Mendelson[SUP]1,2,**[/SUP] , Michal Mandelboim[SUP]1,2,** [/SUP]

SARS-CoV-2 Delta (B.1.617.2) variant of concern (VOC) and other VOCs are spreading in Europe. Micro-neutralisation assays with sera obtained after Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in 36 healthcare workers (31 female) demonstrated significant fold change reduction in neutralising titres compared with the original virus: Gamma (P.1) 2.3, Beta (B.1.351) 10.4, Delta 2.1 and 2.6. The reduction of the Alpha (B.1.1.7) variant was not significant. Despite being lower, remaining neutralisation capacity conferred by Comirnaty against Delta and other VOCs is probably protective.

full article

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.26.2100557#html_fulltext